[{"fields": {"category_code": 1, "latest_date": "2010-03-04", "application_number": "833/KOLNP/2010", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": " PCT/JP2008/064500", "abstract": "A compound represented by the formula (I) according to claim 1 or a salt thereof has a superior androgen receptor modulating action.", "priority_country": "", "hearing_date": null, "filing_date": "2010-03-04", "link": "", "applicant_name": "Takeda Pharmaceutical Company Limited", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Pyrrolidin-2-one derivatives as androgen receptor modulator", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 2}, {"fields": {"category_code": 3, "latest_date": "2015-08-04", "application_number": "6532/DELNP/2008", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2007/004421", "abstract": "\"\"", "priority_country": "US", "hearing_date": "2015-08-04", "filing_date": "2008-07-28", "link": "", "applicant_name": "Bristol-Myers Squibb Company", "created_date": "2016-04-26", "publication_date": "2008-10-24", "title_of_invention": "Method for preventing or treating obesity", "decision": 3, "priority_date": "2006-02-28"}, "model": "ipm.patent", "pk": 6}, {"fields": {"category_code": null, "latest_date": "2015-08-05", "application_number": "7113/DELNP/2008", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2007/062488", "abstract": "", "priority_country": "US", "hearing_date": "2015-08-05", "filing_date": "2008-08-21", "link": "", "applicant_name": "Nektar Therapeutics Al., Corporation", "created_date": "2016-04-26", "publication_date": "2008-10-03", "title_of_invention": "Nektar therapeutics al., corporation", "decision": 3, "priority_date": "2006-02-21"}, "model": "ipm.patent", "pk": 7}, {"fields": {"category_code": null, "latest_date": "2015-08-06", "application_number": "4966/DELNP/2009", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/IB2008/000249", "abstract": "", "priority_country": "USA", "hearing_date": "2015-08-06", "filing_date": "2009-07-30", "link": "", "applicant_name": "Pfizer Products, Inc.", "created_date": "2016-04-26", "publication_date": "2010-03-05", "title_of_invention": "Tricyclic compounds and their use as glucocorticoid receptor modulators", "decision": 3, "priority_date": "2007-02-02"}, "model": "ipm.patent", "pk": 8}, {"fields": {"category_code": null, "latest_date": "2015-08-10", "application_number": "4595/DELNP/2006", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2005/006770", "abstract": "", "priority_country": "US", "hearing_date": "2015-08-10", "filing_date": "2006-08-09", "link": "", "applicant_name": "Baxter International Inc.", "created_date": "2016-04-26", "publication_date": "2007-08-24", "title_of_invention": "Peelable seal closure assembly", "decision": 3, "priority_date": "2004-03-03"}, "model": "ipm.patent", "pk": 9}, {"fields": {"category_code": null, "latest_date": null, "application_number": "2909/KOLNP/2009", "decision_comments": "Objections included Section 2(1)(j)", "status_with_US_EPO": "Published (EPO)", "PCT_number": "PCT/US2008/000926", "abstract": "Provided are pharmaceutical formulations comprising sustained release particles each having an inner core bead comprising an active pharmaceutical ingredient an intermediate coating substantially surrounding the irmer core bead, and an outer coating substantially surrounding the intermediate coating comprising a pH independent polymer. Also provided is a pharmaceutical formulation comprising two bead populations wherein each of the first and second bead populations have a different drug release ", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Mylan Pharmaceuticals, Inc.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Extended-release dosage form", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 10}, {"fields": {"category_code": 3, "latest_date": null, "application_number": "3268/DELNP/2007", "decision_comments": "Application withdrawn by applicant", "status_with_US_EPO": "Granted (USPTO & EPO)", "PCT_number": "PCT/EP2005/056105", "abstract": "The present invention relates to pharmaceutical formulations comprising insulin, an insulin analog, an insulin derivative, or a combination of any of the foregoing, and a salt of protamine, to methods of preparing such formulations, and to uses of such formulations in the treatment of diseases and conditions for which use of the insulin peptide(s) contained in such formulations is indicated. The present invention further relates to methods for increas-ing the stability and/or solubility of insulin in insulin-containing formulations at a pH less than 7.0 by adding a salt of protamine to the insulin-containing formulations.", "priority_country": "DK", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Novo Nordisk A/S.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Soluble, stable insulin-containing formulations with a protamine salt", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 11}, {"fields": {"category_code": null, "latest_date": null, "application_number": "234/KOLNP/2007", "decision_comments": "Initial objections included Section 2(1)(j)", "status_with_US_EPO": "Granted (USPTO & EPO)", "PCT_number": "PCT/US2005/025276", "abstract": "The present invention provides polypeptides, particularly therapeutic antibodies, comprising a novel, variant Fc region. Furthermore the invention provides variant Fc regions which confer an altered effector function or altered serum half life upon a polypeptide to which it is operable attached.", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Applied Molecular Evolution Inc.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Variant FC regions", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 12}, {"fields": {"category_code": null, "latest_date": null, "application_number": "975/DELNP/2007", "decision_comments": "Initial objections included under Sections 2(1)(j) and 3(d)", "status_with_US_EPO": "Granted (USPTO & EPO)", "PCT_number": "PCT/FR2005/002002", "abstract": "The invention relates to a method for the controlled oxidation of oligo- and/or polysaccharides containing free -CH2OH primary hydroxyl groups, using an oxidising agent. The invention is characterised in that the oxidation reaction is performed in a densified fluid which is inert in relation to the oxidising agents employed. The invention is suitable for use, for example, in the food, paint, paper, textile, agricultural and pharmaceutical industries, in the medical, biomedical or paramedical fields, in the surgical field, in the cosmetic industry and as agents for the complexing or sequestering of metal ions, heavy metals and radioactive elements in the nuclear industry.", "priority_country": "FR", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Centre National De La Recherche Scientifique (CNRS", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Method for the controlled oxidation of polysaccharides", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 13}, {"fields": {"category_code": 2, "latest_date": null, "application_number": "3044/CHENP/2008", "decision_comments": "Refused; Divisional application objections included under Section 2(1)(j)", "status_with_US_EPO": "Granted (EPO)", "PCT_number": "PCT/JP04/02085", "abstract": "A method for treating severe heart failure, comprising administering to a patient an effective amount of a benzazepine compound (1): wherein R>1< IS H OR HALOGEN, R>2< IS OH, OR -NR>56< (R>5< AND R>6< are H or lower alkyl, R>3< is H, halogen, lower alkyl, or lower alkoxy, R>4< is halogen, lower alkyl or lower alkoxy, or a salt thereof, and a pharmaceutical composition containing the benzazepine compound (1) or a salt thereof and use of the compound (1) or a salt thereof for preparing a medicament for treatment of severe heart failure.", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Otsuka Pharmaceutical Co. Ltd.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "A pharmaceutical composition comprising benzazepine compound for severe heart failure", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 14}, {"fields": {"category_code": null, "latest_date": null, "application_number": "558/DEL/2008", "decision_comments": "Granted; Initial objections under Sectin 2(1)(j)", "status_with_US_EPO": "", "PCT_number": "", "abstract": "A cartridge for an IOL delivery system that is specifically designed to aid in wound assisted IOL delivery. The distal tip of the nozzle has an extended canopy which serves to open the incision and support the IOL. Peripheral protrusions, flanges, or stops extending laterally from the side of the distal tip provide a positive depth limitation, and prevent the full insertion of the nozzle into the incision. In addition, the protrusion provides support to the incision to reduce the tendency of wound damage through tearing.", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Alcon, Inc.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Lens injector lumen tip for wound assisted delivery", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 15}, {"fields": {"category_code": null, "latest_date": null, "application_number": "1159/CHENP/2008", "decision_comments": "Granted; Initial objections included under Section 3(p)", "status_with_US_EPO": "EPO (Granted)", "PCT_number": "PCT/EP2005/09851", "abstract": "The present invention relates to a pharmaceutical composition comprising an antimalarial agent selected from the group consisting of artemether, arteether, artemisinin, dihydroartemisinin and artesunate; sulfamethoxypyrazine; and a dihydrofolate reductase inhibitor and further comprising one or more pharmaceutical acceptable excipients, carriers and/or diluents suitable for providing treatment of malaria in a period of one day.", "priority_country": "", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Dafra Pharma N.V", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Pharmaceutical composition suitable for the treatment of malaria within one day", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 16}, {"fields": {"category_code": 2, "latest_date": null, "application_number": "1498/DELNP/2006", "decision_comments": "Refused; Applicant did not attend hearing or file responses to objections", "status_with_US_EPO": "Withdrawn (EPO)", "PCT_number": "PCT/US2004/033683", "abstract": "The present invention is directed to a polyaxial bone anchor for attaching a rod to a bone comprising an anchor member for attachment to the bone, a body member having a U shaped channel for receiving the rod and a compressible recess for receiving a head of the anchor member such that the anchor member can initially polyaxially angulate with respect to the body member, a collar sliclably disposed about the body member and capable of compressing the recess around the head, and a fastener capable of pressing the rod against the collar. The body member may define a first axis, an upper bounding edge, and a lower bounding edge, and the lower bounding edge may include a countersunk region to permit increased angulation of the anchor member with respect to the first axis when the anchor member is oriented toward the countersunk region. Cither structures for providing increased angulation of the anchor member arc disclosed as well. Further, the present invention is directed to methods of fixation of the cervical region of the spine.", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Synthes AG Chur", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Polyaxial Bone Anchor", "decision": 2, "priority_date": null}, "model": "ipm.patent", "pk": 17}, {"fields": {"category_code": null, "latest_date": null, "application_number": "4561/KOLNP/2007", "decision_comments": "Refused; Applicant no longer interestd in pursuing application", "status_with_US_EPO": "Withdrawn (EPO)", "PCT_number": "PCT/US2006/016983", "abstract": "Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided.", "priority_country": "US", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "Illumigen Biosciences, Inc.", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "Mutations in oas1 genes", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 18}, {"fields": {"category_code": null, "latest_date": "2015-07-14", "application_number": "6500/DELNP/2006", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2005/018214", "abstract": "", "priority_country": "USA", "hearing_date": "2015-07-14", "filing_date": "2006-11-02", "link": "", "applicant_name": "Genencor International, Inc.", "created_date": "2016-04-26", "publication_date": "2007-08-31", "title_of_invention": "Acid-stable alpha amylases having granular starch hydrolyzing activity and enzyme compositions", "decision": 3, "priority_date": "2004-05-27"}, "model": "ipm.patent", "pk": 20}, {"fields": {"category_code": null, "latest_date": "2015-07-14", "application_number": "1041/DEL/2007", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "", "abstract": "", "priority_country": "", "hearing_date": "2015-07-14", "filing_date": "2007-05-14", "link": "", "applicant_name": "National Institute of Immunology", "created_date": "2016-04-26", "publication_date": "2009-02-13", "title_of_invention": "Process for obtaining bioactive recombinant protein from inclusion bodies", "decision": 3, "priority_date": null}, "model": "ipm.patent", "pk": 21}, {"fields": {"category_code": null, "latest_date": "2015-07-14", "application_number": "2871/DELNP/2007", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/EP2005/011127", "abstract": "", "priority_country": "EU", "hearing_date": "2015-07-14", "filing_date": "2007-04-18", "link": "", "applicant_name": "Vakzine Projekt Management GMBH", "created_date": "2016-04-26", "publication_date": "2007-08-17", "title_of_invention": "Combination of a bacterial cell and a biologically active agent", "decision": null, "priority_date": "2004-10-21"}, "model": "ipm.patent", "pk": 22}, {"fields": {"category_code": 3, "latest_date": "2015-07-15", "application_number": "5543/DELNP/2008", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2007/060115", "abstract": "", "priority_country": "USA", "hearing_date": "2015-07-15", "filing_date": "2008-06-25", "link": "", "applicant_name": "Genentech, Inc.", "created_date": "2016-04-26", "publication_date": "2008-09-26", "title_of_invention": "Anti-ephb4 antibodies and methods using same", "decision": null, "priority_date": "2006-01-05"}, "model": "ipm.patent", "pk": 23}, {"fields": {"category_code": null, "latest_date": "2015-07-15", "application_number": "3570/DELNP/2006", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/GB2004/004929", "abstract": "", "priority_country": "UK", "hearing_date": "2015-07-15", "filing_date": "2006-06-20", "link": "", "applicant_name": "Cobra Biologics Limited", "created_date": "2016-04-26", "publication_date": "2007-08-31", "title_of_invention": "Plasmid maintenance", "decision": null, "priority_date": "2003-11-20"}, "model": "ipm.patent", "pk": 24}, {"fields": {"category_code": null, "latest_date": "2015-07-15", "application_number": "1341/DELNP/2008", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/US2006/031651", "abstract": "", "priority_country": "USA", "hearing_date": "2015-07-15", "filing_date": "2008-02-15", "link": "", "applicant_name": "Wyeth", "created_date": "2016-04-26", "publication_date": "2008-06-27", "title_of_invention": "Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-assoclated disorders", "decision": null, "priority_date": "2005-08-19"}, "model": "ipm.patent", "pk": 25}, {"fields": {"category_code": null, "latest_date": "2015-07-16", "application_number": "2878/DELNP/2009", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/IB2007/003202", "abstract": "", "priority_country": "USA", "hearing_date": "2015-07-16", "filing_date": "2009-04-30", "link": "", "applicant_name": "Pfizer Product, Inc.", "created_date": "2016-04-26", "publication_date": "2009-06-19", "title_of_invention": "Biaryl ether urea compounds", "decision": null, "priority_date": "2006-10-18"}, "model": "ipm.patent", "pk": 26}, {"fields": {"category_code": null, "latest_date": "2015-07-17", "application_number": "5616/DELNP/2008", "decision_comments": "", "status_with_US_EPO": "", "PCT_number": "PCT/EP2006/012331", "abstract": "", "priority_country": "EPO", "hearing_date": "2015-07-17", "filing_date": "2008-06-27", "link": "", "applicant_name": "DSM IP Assets B.V", "created_date": "2016-04-26", "publication_date": "2008-09-26", "title_of_invention": "Process for the treatment of an aqueous mixture comprising a dipolar aprotic compound", "decision": null, "priority_date": "2005-12-20"}, "model": "ipm.patent", "pk": 27}, {"fields": {"category_code": null, "latest_date": "2004-01-01", "application_number": "2618/DEL/2004", "decision_comments": "Granted; Initial objections under Section 2(1)(j) and 3(j)", "status_with_US_EPO": "", "PCT_number": "", "abstract": "An antibiotic-free marker system for transgenic plants is disclosed. The marker system comprising one or more glyoxalases selected from glyoxalase I and II genes cloned on a vector.", "priority_country": "", "hearing_date": null, "filing_date": null, "link": "", "applicant_name": "International Centre for Genetic Engineering Biote", "created_date": "2016-04-26", "publication_date": null, "title_of_invention": "A novel selectable marker system for transgenic plants", "decision": 1, "priority_date": null}, "model": "ipm.patent", "pk": 28}]